Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Biofrontera (BFRIW) Change in Accured Expenses (2020 - 2025)

Biofrontera has reported Change in Accured Expenses over the past 6 years, most recently at -$1.7 million for Q4 2025.

  • Quarterly results put Change in Accured Expenses at -$1.7 million for Q4 2025, down 321.32% from a year ago — trailing twelve months through Dec 2025 was $610000.0 (up 365.22% YoY), and the annual figure for FY2025 was $610000.0, up 365.22%.
  • Change in Accured Expenses for Q4 2025 was -$1.7 million at Biofrontera, down from $746000.0 in the prior quarter.
  • Over the last five years, Change in Accured Expenses for BFRIW hit a ceiling of $6.2 million in Q3 2023 and a floor of -$12.5 million in Q4 2023.
  • Median Change in Accured Expenses over the past 5 years was $57500.0 (2021), compared with a mean of -$291600.0.
  • Biggest five-year swings in Change in Accured Expenses: surged 4114.63% in 2022 and later plummeted 379.02% in 2023.
  • Biofrontera's Change in Accured Expenses stood at -$1.1 million in 2021, then crashed by 141.17% to -$2.6 million in 2022, then plummeted by 379.02% to -$12.5 million in 2023, then skyrocketed by 96.84% to -$394000.0 in 2024, then crashed by 321.32% to -$1.7 million in 2025.
  • The last three reported values for Change in Accured Expenses were -$1.7 million (Q4 2025), $746000.0 (Q3 2025), and $1.2 million (Q2 2025) per Business Quant data.